Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)
With its controversial aducanumab approval in hand, Biogen gears up for a quick US rollout
In what will prove to be a controversial decision for years to come, the FDA earlier this week approved Biogen’s aducanumab for Alzheimer’s disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
